Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Dermata Therapeutics, Inc. - Common Stock (NQ:DRMA)

2.504 -0.576 (-18.70%)
Streaming Delayed Price Updated: 3:47 PM EST, Jan 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Dermata Therapeutics, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
Dermata to Present at the H.C. Wainwright BioConnect Conference
SAN DIEGO, CA / ACCESSWIRE / January 5, 2022 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and... 
From Dermata Therapeutics
Via AccessWire
News headline image
54 Biggest Movers From Yesterday ↗
Gainers Siyata Mobile Inc. (NASDAQ: SYTA) shares jumped 66.7% to close at $4.60 on Tuesday. Siyata Mobile received $1.3 million purchase order for SD7 ruggedized devices and... 
Via Benzinga
News headline image
36 Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Siyata Mobile Inc. (NASDAQ: SYTA) shares climbed 123.2% to $6.16. Siyata Mobile received $1.3 million purchase order for SD7 ruggedized devices and accessories.... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Gainers Pasithea Therapeutics (NASDAQ:KTTA) stock increased by 157.46% to $5.69 during Tuesday's pre-market session. The company's market cap stands at $75.1... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Gainers iSpecimen (NASDAQ:ISPC) stock moved upwards by 95.32% to $9.61 during Monday's regular session. Trading volume for iSpecimen's stock is 70.9 million as of... 
Via Benzinga
News headline image
50 Biggest Movers From Yesterday ↗
Gainers Krystal Biotech, Inc. (NASDAQ: KRYS) shares surged 121.7% to close at $88.24 on Monday after the company announced positive topline results from the GEM-3 Phase 3 trial... 
Via Benzinga
News headline image
Dermata's Aesthetic Improvement Candidate Fails To Impress - Read Why ↗
Dermata Therapeutics Inc (NASDAQ: DRMA) announced data from its Phase 1b proof of concept study evaluating a single treatment of DMT410 to treat multiple aesthetic... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
Gainers SCYNEXIS (NASDAQ:SCYX) stock rose 15.69% to $7.15 during Friday's regular session. As of 12:30 EST, this security is trading at a volume of 1.2 million shares... 
Via Benzinga
News headline image
68 Biggest Movers From Wednesday ↗
Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) shares gained 689.4% to settle at $78.94 on Wednesday after the company priced its IPO at $10 per share. Longeveron Inc. (... 
Via Benzinga
Topics Initial Public Offering
News headline image
Dermata Announces Positive Results from DMT410 Phase 1b Proof of Concept Study for Aesthetic Skin Conditions
- Observed improvements in pore size, luminosity, brightness, and overall aesthetic appearance - Duration of effect lasted approximately 3 months - No potential distant spread of toxin observed SAN... 
From Dermata Therapeutics
Via AccessWire
News headline image
61 Biggest Movers From Yesterday ↗
Gainers Longeveron Inc. (NASDAQ: LGVN) shares surged 181.2% to settle at $28.20 on Monday on continued upward momentum after the company last week announced the FDA granted Rare... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Connect Biopharma Sinks On Eczema Drug Readout, Enanta Pulls Plug On HBV Drug, Clinical Setback For Merck In HIV Trial ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Connect Biopharma Atopic Dermatitis Treatment Aces Mid-stage Study But Lack... 
Via Benzinga
News headline image
52 Biggest Movers From Friday ↗
Gainers Greenland Technologies Holding Corporation (NASDAQ: GTEC) shares surged 90.2% to close at $9.89 on Friday. Greenland Technologies highlighted the launch of second... 
Via Benzinga
News headline image
Dermata Announces First Patient Enrolled in its Phase 2 Trial of DMT310 for the Treatment of Moderate-to-Severe Rosacea
- Topline results expected in second half of 2022 - Rosacea affects about 16 million patients in the U.S. SAN DIEGO, CA / ACCESSWIRE / November 17, 2021 / Dermata Therapeutics, Inc. ("Dermata," or the... 
From Dermata Therapeutics
Via AccessWire
News headline image
Dermata Therapeutics, Inc. Reports Third Quarter 2021 Financial Results and Provides Corporate Update
- Announced positive topline results from DMT310 proof of concept (POC) study in mild-to-moderate psoriasis - - Closed upsized $18.0 million initial public offering (IPO) on Nasdaq Capital Market - -... 
From Dermata Therapeutics
Via AccessWire
Topics Initial Public Offering
News headline image
The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More ↗
Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at... 
Via Benzinga
News headline image
Dermata Announces Presentation Details for Its DMT410 Phase 1b Proof of Concept Aesthetic Study at The American Society for Dermatologic Surgery (ASDS) 2021 Annual Meeting
SAN DIEGO, CA / ACCESSWIRE / November 12, 2021 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (Nasdaq:DRMA), a clinical-stage biotechnology company focusing on the treatment of medical and... 
From Dermata Therapeutics
Via AccessWire
News headline image
Dermata Announces Virtual Investor Event to Present DMT410 Phase 1b Proof of Concept Results in Aesthetic Skin Conditions
SAN DIEGO, CA / ACCESSWIRE / November 11, 2021 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA), a clinical-stage biotechnology company focusing on the treatment of medical and... 
From Dermata Therapeutics
Via AccessWire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Gainers Entasis Therapeutics Hldg (NASDAQ:ETTX) shares moved upwards by 16.72% to $3.63 during Tuesday's pre-market session. The company's market cap stands at $... 
Via Benzinga
News headline image
18 Stocks Moving in Tuesday's Pre-Market Session ↗
Gainers Kaival Brands Innovations Group, Inc. (NASDAQ: KAVL) rose 26.1% to $2.03 in pre-market trading after surging 18% on Monday. Kaival Brands Innovations recently announced... 
Via Benzinga
News headline image
Dermata Stock Jumps On Positive Psoriasis Candidate Data ↗
Dermata Therapeutics Inc (NASDAQ: DRMA) announced topline results from its Phase 1b trial of DMT310 for mild-to-moderate psoriasis. The percentage of treatment... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Gainers Dermata Therapeutics (NASDAQ:DRMA 
Via Benzinga
News headline image
Dermata Announces Positive Results from Phase 1b Clinical Trial of DMT310 for the Treatment of Mild-to-Moderate Psoriasis
- DMT310 achieved a PGA score of 0 or 1 for the target lesion in 29.6% of patients at Week 8 - - DMT310 demonstrated a total PASI score of 0 or 1 for the target lesion in 25.9% of patients at Week 8 -... 
From Dermata Therapeutics
Via AccessWire
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
Gainers NuCana (NASDAQ:NCNA) stock increased by 22.36% to $2.9 during Wednesday's regular session. The current volume of 77.9 million shares is 21650.59% of NuCana... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc. (... 
Via Benzinga
News headline image
Dermata Therapeutics, Inc. Reports Second Quarter 2021 Financial Results and Provides Corporate Update
- Completed oversubscribed $18 million Initial Public Offering (IPO) - - Set to announce topline results from its DMT310 Phase 1b proof of concept (POC) study in mild to moderate psoriasis in 4Q 2021 -... 
From Dermata Therapeutics
Via AccessWire
Topics Initial Public Offering Intellectual Property
News headline image
50 Biggest Movers From Yesterday ↗
Gainers Marin Software Incorporated (NASDAQ: MRIN) shares jumped 61.9% to close at $9.21 on Wednesday following an announcement from management that the company entered into a... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
Gainers Regencell Bioscience (NASDAQ: 
Via Benzinga
News headline image
32 Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Marin Software Incorporated (NASDAQ: MRIN) shares climbed 53.1% to $8.71 following an announcement from management that the company entered into a revenue share... 
Via Benzinga
News headline image
Why Are Dermata Therapeutics Shares Trading Higher Today? ↗
Brookline has initiated Dermata Therapeutics Inc's (NASDAQ: DRMA) coverage with a Buy rating and $14 price target. Analyst Kumaraguru Raja sees an upside of... 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.